ProCE Banner Activity

Applying Immuno-Oncology Combinations as First-line Therapy for Advanced RCC

Clinical Thought
How do you select first-line therapy for your patients with advanced RCC? In this commentary, Drs. Brian A. Costello and Martin H. Voss discuss the latest clinical data on immuno-oncology combinations for frontline therapy in advanced RCC.

Released: August 18, 2020

Expiration: August 17, 2021

No longer available for credit.

Share

Faculty

Brian A. Costello

Brian A. Costello, MD, MS

Associate Professor of Oncology and Urology
Consultant

Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Martin H. Voss

Martin H. Voss, MD

Attending Physician
Division of GU Medical Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor

Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from
Eisai
Pfizer and EMD Serono

Supported by a medical education grant from
Exelixis, Inc.
Supported by an independent educational grant from

Merck Oncology

Partners

NCCN

ProCE Banner

Faculty Disclosure

Primary Author

Brian A. Costello, MD, MS

Associate Professor of Oncology and Urology
Consultant

Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Brian A. Costello, MD, has no relevant conflicts of interest to report.

Martin H. Voss, MD

Attending Physician
Division of GU Medical Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor

Weill Cornell Medical College
New York, New York

Martin H. Voss, MD, has disclosed that he has received consulting fees from Calithera, Corvus, Eisai, Exelixis, GlaxoSmithKline, Novartis, and Pfizer; funds for research support from Bristol-Myers Squibb, Genentech, and Pfizer; and fees for non-CME/CE services from AstraZeneca, Eisai, and Takeda.